Andrew R Williams1, Gary D Hammer1, Tobias Else2. 1. University of Michigan Medical School1301 Catherine Street, Ann Arbor, Michigan 48109, USADivision of MetabolismEndocrinology and Diabetes (MEND), Department of Internal Medicine, University of Michigan Hospital and Health Systems, NI3 A17, 300 North Ingalls, Ann Arbor, Michigan 48109-5419, USA. 2. University of Michigan Medical School1301 Catherine Street, Ann Arbor, Michigan 48109, USADivision of MetabolismEndocrinology and Diabetes (MEND), Department of Internal Medicine, University of Michigan Hospital and Health Systems, NI3 A17, 300 North Ingalls, Ann Arbor, Michigan 48109-5419, USA telse@umich.edu.
Abstract
CONTEXT: Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence and mortality rates. The utility, sensitivity, and effect on patient outcome of transcutaneous adrenal biopsy (TAB) for single, large, adrenal masses are unclear. OBJECTIVE: This study evaluated the utility, diagnostic sensitivity, and effect on patient outcome of TAB in patients with ACC. DESIGN AND SETTING: We conducted a retrospective review of the electronic medical records of all ACC patients who were evaluated at the University of Michigan Health System from 1991 to 2011. We evaluated the sensitivity of TAB for tumors with the final pathological diagnosis of ACC. We compared the characteristics and survival of patients with stage I-III disease who underwent TAB with those who did not undergo TAB. RESULTS: A total of 75 ACC patients with TAB were identified. Complications occurred in at least 11% of patients and were mainly associated with bleeding. The maximum sensitivity of the procedure in diagnosing ACC was 70%. For stage I-III patients, baseline characteristics, stage at diagnosis, and adjuvant treatment with mitotane or radiation were not significantly different between the TAB (n=36) and the non-TAB (n=254) groups. There was no significant difference in recurrence-free (P=0.7) or overall survival (P=0.7) between patients who underwent TAB and those who did not. CONCLUSIONS: TAB of single, large, adrenal masses is usually unnecessary, exposes patients to risk, but does not affect recurrence-free or overall survival.
CONTEXT: Adrenocortical carcinoma (ACC) is a rare malignancy with high recurrence and mortality rates. The utility, sensitivity, and effect on patient outcome of transcutaneous adrenal biopsy (TAB) for single, large, adrenal masses are unclear. OBJECTIVE: This study evaluated the utility, diagnostic sensitivity, and effect on patient outcome of TAB in patients with ACC. DESIGN AND SETTING: We conducted a retrospective review of the electronic medical records of all ACC patients who were evaluated at the University of Michigan Health System from 1991 to 2011. We evaluated the sensitivity of TAB for tumors with the final pathological diagnosis of ACC. We compared the characteristics and survival of patients with stage I-III disease who underwent TAB with those who did not undergo TAB. RESULTS: A total of 75 ACC patients with TAB were identified. Complications occurred in at least 11% of patients and were mainly associated with bleeding. The maximum sensitivity of the procedure in diagnosing ACC was 70%. For stage I-III patients, baseline characteristics, stage at diagnosis, and adjuvant treatment with mitotane or radiation were not significantly different between the TAB (n=36) and the non-TAB (n=254) groups. There was no significant difference in recurrence-free (P=0.7) or overall survival (P=0.7) between patients who underwent TAB and those who did not. CONCLUSIONS:TAB of single, large, adrenal masses is usually unnecessary, exposes patients to risk, but does not affect recurrence-free or overall survival.
Authors: Aaron Sabolch; Mary Feng; Kent Griffith; Gary Hammer; Gerard Doherty; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-01 Impact factor: 7.038
Authors: Sarah Johanssen; Stefanie Hahner; Wolfgang Saeger; Marcus Quinkler; Felix Beuschlein; Henning Dralle; Michaela Haaf; Matthias Kroiss; Christian Jurowich; Peter Langer; Wolfgang Oelkers; Martin Spahn; Holger S Willenberg; Uwe Mäder; Bruno Allolio; Martin Fassnacht Journal: Dtsch Arztebl Int Date: 2010-12-17 Impact factor: 5.594
Authors: M Terzolo; A Stigliano; I Chiodini; P Loli; L Furlani; G Arnaldi; G Reimondo; A Pia; V Toscano; M Zini; G Borretta; E Papini; P Garofalo; B Allolio; B Dupas; F Mantero; A Tabarin Journal: Eur J Endocrinol Date: 2011-04-06 Impact factor: 6.664
Authors: Kimberly A Vanderveen; Scott M Thompson; Matthew R Callstrom; William F Young; Clive S Grant; David R Farley; Melanie L Richards; Geoffrey B Thompson Journal: Surgery Date: 2009-12 Impact factor: 3.982
Authors: Buelent Polat; Martin Fassnacht; Leo Pfreundner; Matthias Guckenberger; Klaus Bratengeier; Sarah Johanssen; Werner Kenn; Stefanie Hahner; Bruno Allolio; Michael Flentje Journal: Cancer Date: 2009-07-01 Impact factor: 6.860
Authors: Martin Fassnacht; Sarah Johanssen; Marcus Quinkler; Peter Bucsky; Holger S Willenberg; Felix Beuschlein; Massimo Terzolo; Hans-Helge Mueller; Stefanie Hahner; Bruno Allolio Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: Levent Ozsari; Merve Kutahyalioglu; Khaled M Elsayes; Rafael Andres Vicens; Kanishka Sircar; Tarek Jazaerly; Steven G Waguespack; Naifa L Busaidy; Maria E Cabanillas; Ramona Dadu; Mimi I Hu; Rena Vassilopoulou-Sellin; Camilo Jimenez; Jeffrey E Lee; Mouhammed Amir Habra Journal: Endocrine Date: 2015-07-25 Impact factor: 3.633
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Michaela Kuhlen; Christina Pamporaki; Marina Kunstreich; Stefan A Wudy; Michaela F Hartmann; Mirko Peitzsch; Christian Vokuhl; Guido Seitz; Michael C Kreissl; Thorsten Simon; Barbara Hero; Michael C Frühwald; Peter Vorwerk; Antje Redlich Journal: Front Endocrinol (Lausanne) Date: 2022-06-17 Impact factor: 6.055
Authors: Péter István Turai; Zoltán Herold; Gábor Nyirő; Katalin Borka; Tamás Micsik; Judit Tőke; Nikolette Szücs; Miklós Tóth; Attila Patócs; Peter Igaz Journal: Cancers (Basel) Date: 2022-02-11 Impact factor: 6.639